Overview
Clinical evidence and decision-support AI for physicians and health systems.
What OpenEvidence does
OpenEvidence helps clinicians investigate medical questions against clinical literature and other medical knowledge sources. It produces source-linked answers for use at the point of care, with deeper research available through its DeepConsult capability.
The platform also supports clinical communications through Doctor Dialer, bringing calls, messaging and voicemail into the same environment as its evidence tools. Its users are medical professionals; it supplies decision-support software rather than operating a medical practice.
OpenEvidence Enterprise adds institutional identity, agreements, access controls and a deployment path into EHR workflows. Health systems can establish organization-level governance and retention arrangements while making the clinical resource available to verified U.S. clinicians.
Pricing
OpenEvidence publishes no-cost enterprise access for eligible care-delivery organizations.
- Enterprise institutional access
- No cost for eligible organizations
- Available to health systems and care-delivery organizations supporting verified U.S. clinicians, with institutional setup and governance.
Company details
- Funding
- $210 million Series B (July 2025; historical round)
Founders & leadership
Investors & backers
Historical round: OpenEvidence announced a $210 million Series B on July 15, 2025, co-led by GV and Kleiner Perkins. This describes that financing, not a current total-funding figure.
GV
Kleiner Perkins
Sequoia Capital- Coatue
- Conviction
- Thrive Capital
